Immunomodulators as therapeutic strategies for managing multiple sclerosis

E. W. Brenu, L. Tajouri, D. R. Staines, S. Marshall-Gradisnik

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

Abstract

Immunomodulation and immunosuppression are important strategies for monitoring autoimmune disorders. As imbalances in immune function affect other physiological processes, immunomodulators may have an important role in restoring and maintaining regular neuroimmue activities. In recent years these agents have demonstrated important benefits in controlling the mechanisms associated with deteriorating central nervous system pathologies such as Multiple Sclerosis (MS), where central and peripheral nervous system immune regulation is impaired. MS is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

Original languageEnglish
Title of host publicationAutoimmune Disorders: Symptoms, Diagnosis and Treatment
EditorsME Petrov
Place of PublicationUnited States
PublisherNova Science Publishers
Pages249-266
Number of pages18
ISBN (Print)9781617615528
Publication statusPublished - Jan 2011

Fingerprint

Immunologic Factors
Multiple Sclerosis
Neuroimmunomodulation
Central Nervous System
Physiological Phenomena
Therapeutics
Phosphodiesterase Inhibitors
Immunomodulation
Peripheral Nervous System
Neuropeptides
Immunosuppression
Interferons
Immune System
Pathology
Proteins

Cite this

Brenu, E. W., Tajouri, L., Staines, D. R., & Marshall-Gradisnik, S. (2011). Immunomodulators as therapeutic strategies for managing multiple sclerosis. In ME. Petrov (Ed.), Autoimmune Disorders: Symptoms, Diagnosis and Treatment (pp. 249-266). United States: Nova Science Publishers.
Brenu, E. W. ; Tajouri, L. ; Staines, D. R. ; Marshall-Gradisnik, S. / Immunomodulators as therapeutic strategies for managing multiple sclerosis. Autoimmune Disorders: Symptoms, Diagnosis and Treatment. editor / ME Petrov. United States : Nova Science Publishers, 2011. pp. 249-266
@inbook{eb6eb8b7e89843a4aff1d3f438331e63,
title = "Immunomodulators as therapeutic strategies for managing multiple sclerosis",
abstract = "Immunomodulation and immunosuppression are important strategies for monitoring autoimmune disorders. As imbalances in immune function affect other physiological processes, immunomodulators may have an important role in restoring and maintaining regular neuroimmue activities. In recent years these agents have demonstrated important benefits in controlling the mechanisms associated with deteriorating central nervous system pathologies such as Multiple Sclerosis (MS), where central and peripheral nervous system immune regulation is impaired. MS is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.",
author = "Brenu, {E. W.} and L. Tajouri and Staines, {D. R.} and S. Marshall-Gradisnik",
year = "2011",
month = "1",
language = "English",
isbn = "9781617615528",
pages = "249--266",
editor = "ME Petrov",
booktitle = "Autoimmune Disorders: Symptoms, Diagnosis and Treatment",
publisher = "Nova Science Publishers",

}

Brenu, EW, Tajouri, L, Staines, DR & Marshall-Gradisnik, S 2011, Immunomodulators as therapeutic strategies for managing multiple sclerosis. in ME Petrov (ed.), Autoimmune Disorders: Symptoms, Diagnosis and Treatment. Nova Science Publishers, United States, pp. 249-266.

Immunomodulators as therapeutic strategies for managing multiple sclerosis. / Brenu, E. W.; Tajouri, L.; Staines, D. R.; Marshall-Gradisnik, S.

Autoimmune Disorders: Symptoms, Diagnosis and Treatment. ed. / ME Petrov. United States : Nova Science Publishers, 2011. p. 249-266.

Research output: Chapter in Book/Report/Conference proceedingChapterResearchpeer-review

TY - CHAP

T1 - Immunomodulators as therapeutic strategies for managing multiple sclerosis

AU - Brenu, E. W.

AU - Tajouri, L.

AU - Staines, D. R.

AU - Marshall-Gradisnik, S.

PY - 2011/1

Y1 - 2011/1

N2 - Immunomodulation and immunosuppression are important strategies for monitoring autoimmune disorders. As imbalances in immune function affect other physiological processes, immunomodulators may have an important role in restoring and maintaining regular neuroimmue activities. In recent years these agents have demonstrated important benefits in controlling the mechanisms associated with deteriorating central nervous system pathologies such as Multiple Sclerosis (MS), where central and peripheral nervous system immune regulation is impaired. MS is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

AB - Immunomodulation and immunosuppression are important strategies for monitoring autoimmune disorders. As imbalances in immune function affect other physiological processes, immunomodulators may have an important role in restoring and maintaining regular neuroimmue activities. In recent years these agents have demonstrated important benefits in controlling the mechanisms associated with deteriorating central nervous system pathologies such as Multiple Sclerosis (MS), where central and peripheral nervous system immune regulation is impaired. MS is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

UR - http://www.scopus.com/inward/record.url?scp=84891972535&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617615528

SP - 249

EP - 266

BT - Autoimmune Disorders: Symptoms, Diagnosis and Treatment

A2 - Petrov, ME

PB - Nova Science Publishers

CY - United States

ER -

Brenu EW, Tajouri L, Staines DR, Marshall-Gradisnik S. Immunomodulators as therapeutic strategies for managing multiple sclerosis. In Petrov ME, editor, Autoimmune Disorders: Symptoms, Diagnosis and Treatment. United States: Nova Science Publishers. 2011. p. 249-266